{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=55", "query": { "intervention": "Placebo; placebo comparator condition", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 7773, "total_pages": 778, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T16:46:21.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00177671", "title": "Antidepressant Medication Plus Donepezil for Treating Late-life Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression", "Dementia" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Donepezil", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 220, "start_date": "2003-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2013-02-06", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00177671" }, { "nct_id": "NCT06545929", "title": "Study of Sunobinop on Craving in Alcohol Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Sunobinop", "type": "DRUG" }, { "name": "Placebo to match sunobinop", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Knoa Pharma LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-01-28", "completion_date": "2025-07-14", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545929" }, { "nct_id": "NCT06075095", "title": "A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COPD (Chronic Obstructive Pulmonary Disease)" ], "interventions": [ { "name": "BGF MDI HFO 320/14.4/9.6μg", "type": "DRUG" }, { "name": "BGF MDI HFA 320/14.4/9.6 μg", "type": "DRUG" }, { "name": "Placebo MDI HFA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 297, "start_date": "2024-01-11", "completion_date": "2025-08-12", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 19, "location_summary": "Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075095" }, { "nct_id": "NCT05085275", "title": "Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia, Iron Deficiency", "Hyperphosphatemia", "Renal Insufficiency, Chronic", "Renal Anemia", "Disease Progression", "Cardiovascular", "Iron" ], "interventions": [ { "name": "Ferric Citrate 1 GM Oral Tablet [AURYXIA]", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "USRC Kidney Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 289, "start_date": "2022-03-30", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 23, "location_summary": "Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more", "locations": [ { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05085275" }, { "nct_id": "NCT02637557", "title": "A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Reflux Disease" ], "interventions": [ { "name": "IW-3718", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "PPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ironwood Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2016-03-01", "completion_date": "2017-04-26", "has_results": true, "last_update_posted_date": "2019-10-15", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 62, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02637557" }, { "nct_id": "NCT00560612", "title": "Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Stress Disorders, Post-Traumatic" ], "interventions": [ { "name": "Paroxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Durham VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2006-01", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00560612" }, { "nct_id": "NCT05257265", "title": "A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "Centanafadine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 459, "start_date": "2022-02-02", "completion_date": "2023-10-05", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05257265" }, { "nct_id": "NCT02901431", "title": "A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO5285119", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 339, "start_date": "2016-11-21", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2021-02-08", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 45, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02901431" }, { "nct_id": "NCT04693637", "title": "Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Adenovirus Infection", "BK Virus Infection", "Cytomegalovirus Infections", "Epstein-Barr Virus Infections", "Human Herpes Virus-6 Infection", "JC Virus Infection" ], "interventions": [ { "name": "Posoleucel (ALVR105)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 26, "start_date": "2021-01-15", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Northwest Rectangle", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04693637" }, { "nct_id": "NCT00405275", "title": "Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo, triple", "type": "DRUG" }, { "name": "Placebo, etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2007-07", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-12-03", "last_synced_at": "2026-10-17T16:46:21.481Z", "location_count": 28, "location_summary": "Loma Linda, California • Long Beach, California • San Francisco, California + 23 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Sepulveda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405275" } ] }